Intercept granted Servier rights to its G protein-coupled bile acid receptor 1 (GPBAR1; TGR5) agonist program for Type II diabetes and other metabolic disorders

Intercept Pharmaceuticals Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Servier

France / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced